

R

08-20-2001

ET

TO THE COMMISSIONER FOR PATENTS A



Original documents or copy thereof.

Name of conveying party(ies): (If mul. numerically)

101816398

Name of receiving party(ies):

IMPERIAL BANK

8-201

Name: Alliance Pharmaceutical Corp. Internal Address: Legal Department Street Address: 3040 Science Park Road City: San Diego State: CA ZIP: 92121

Additional name(s) of conveying party(ies) attached? ( ) Yes (X) No

Additional name(s) of receiving party(ies) attached? ( ) Yes (X) No

2. Nature of conveyance:

4. Application number(s) or Registration number(s):

- ( ) Assignment ( ) Merger (X) Release of Security Interest ( ) Change of Name ( ) Other:

- ( ) Application(s) filed herewith Execution Date(s): ( ) Trademark Application No.: (X) Trademark Registration No.: 2,285,943

Execution Date: (If multiple assignors, list execution dates in numerical order corresponding to numbers indicated in 1 above) 1. June 20, 2001

Additional numbers attached? ( ) Yes (X) No

3. Name and address of party to whom correspondence concerning document should be mailed:

7. Total fee (37 CFR 3.41): \$40.00

Name: John Wurst, Patent Counsel Alliance Pharmaceutical Corp. Internal Address: Legal Department Street Address: 3040 Science Park Road City: San Diego State: CA ZIP: 92121 Tel: (858) 410-5174 Fax: (858) 410-5343

- ( ) Check Enclosed (X) Authorized to be charged to deposit account if any additional fees are required, or to credit any overpayment

8. Deposit account number: 01-1008

6. Total number of applications and registrations involved: 1

Please charge this account for any additional fees, which may be required, or credit any overpayment to this account.

4. Statement and signature.

To the best of my knowledge and belief, the foregoing information is true and correct, and any attached copy is a true copy of the original document.

John Wurst, Patent Counsel and Assistant Secretary Name of Person Signing

Signature

7/30/2007 Date

Registration No. 40,283

Total number of pages including cover sheet, attachments and document: 5

Mail documents to be recorded with required cover sheet information to:

Commissioner for Patents and Trademarks Box Assignments Washington, D.C. 20231

08/17/2001 DBYRME 00000071 011008 2285943 01 FC:481 40.00 CH

TRADEMARK REEL: 002350 FRAME: 0627



**SECOND AMENDMENT  
TO INTELLECTUAL PROPERTY SECURITY AGREEMENT**

**THIS SECOND AMENDMENT TO INTELLECTUAL PROPERTY SECURITY AGREEMENT (this "Amendment"), dated June 20, 2001, is entered into by and between Imperial Bank, a California banking corporation ("Secured Party") and Alliance Pharmaceutical Corp., a New York Corporation ("Borrower").**

**RECITALS**

**WHEREAS, in order to secure its indebtedness to Secured Party, Borrower entered into that certain Intellectual Property Security Agreement, dated May 17, 1999 (the "Agreement") pursuant to which Borrower has granted a security interest in and to the Intellectual Property Collateral in favor of Secured Party;**

**WHEREAS, Secured Party has agreed to release certain Intellectual Property Collateral from the Agreement; and**

**WHEREAS, the parties desire to amend the Agreement to release certain Intellectual Property Collateral therefrom as set forth herein.**

**NOW, THEREFORE, in consideration of the premises and the mutual covenants contained herein, the parties agree as follows:**

- 1. The definition of "Intellectual Property Collateral" contained in Section 2 of the Agreement hereby is amended by adding the following new paragraph its entirety immediately following the existing final paragraph thereof as follows:**

**Anything contained in the forgoing to the contrary notwithstanding, the word "Intellectual Property Collateral" shall exclude all now owned or hereafter acquired general intangibles consisting of Copyrights, Licenses, Patents, Trademarks, Trade Secrets and any related files and records covering or relating to any aspect of *RODA*®, including, without limitation, those certain patents and trademarks listed on Exhibit "A" attached hereto and made a part hereof by this reference.**

- 2. Secured Party agrees to execute a UCC release, appropriate releases to be filed in the U.S. Patent and Trademark Office and any other releases reasonably necessary to evidence the agreements contained herein.**
- 3. Unless otherwise defined, all initially capitalized terms in this Amendment shall be as defined in the Agreement. The Agreement, as amended hereby, shall be and remain in full force and effect in accordance with its respective terms and hereby is ratified and confirmed in all respects. Except as expressly set forth herein, the execution, delivery, and performance of this Amendment shall not operate as a waiver of, or as an amendment of, any right, power, or remedy of Lender under the Agreement, as in effect prior to the date hereof. Grantor ratifies and reaffirms the continuing effectiveness of all promissory notes, guaranties, security agreements, mortgages, deeds of trust, environmental agreements, and**

all other instruments, documents and agreements entered into in connection with the Agreement.


4. Grantor represents and warrants that the Representations and Warranties contained in the Agreement are true and correct as of the date of this Amendment, and that no Event of Default has occurred and is continuing.
5. This Amendment may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one instrument.

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed by their duly authorized representatives, all intending to be legally bound hereby.

ALLIANCE PHARMACEUTICAL CORP.

IMPERIAL BANK

By:



Lloyd A. Rowland  
Vice President and General Counsel

By:



Michael A. Berrier  
Senior Vice President



**TRADEMARK PORTFOLIO**

<b>Trademark</b>	<b>Country</b>	<b>Application No. / Registration No.</b>	<b>Registered</b>
<b>RODA®</b>	<b>United States</b>	<b>75/235,237 2,285,943</b>	<b>12 October 1999</b>

**PATENTS AND PATENT APPLICATIONS:**

***RODA® SUMMARY***

**(Exclusively Licensed to VIA Medical Corporation)**

<b>Country</b>	<b>Patent No. / Application No. (Patents in bold)</b>	<b>Licensed/Owned</b>
<b>U.S.</b>	<b>08/487,086</b> <b>5,634,461</b>	<b>O</b>
<b>Europe</b>	<b>96921505.2</b>	<b>O</b>
<b>Australia</b>	<b>62717/96</b> <b>717271</b>	<b>O</b>
<b>Canada</b>	<b>2221995</b>	<b>O</b>
<b>Japan</b>	<b>502140/1997</b>	<b>O</b>
<b>China</b>	<b>96195916.9</b> <b>(Abandoned)</b>	<b>O</b>
<b>Israel</b>	<b>122240</b>	<b>O</b>

<b>Country</b>	<b>Patent No. / Application No. (Patents in bold)</b>	<b>Licensed/Owned</b>
<b>New Zealand</b>	311397 <b>311397</b>	O
<b>Hungary</b>	40938/97 (Abandoned)	O
<b>Norway</b>	975319 (Abandoned)	O
<b>South Korea</b>	708974/1997 (Abandoned)	O
<b>Mexico</b>	979563	O
<b>Poland</b>	P323873	O
<b>U.S.</b>	08/764,607	O
<b>PCT</b>	US97/22808 (National Phase entered)	O
<b>Australia</b>	56008/98	O
<b>Canada</b>	2274523	O
<b>China</b>	97181747.2	O
<b>Japan</b>	10-526982	O
<b>Europe</b>	97952390.9	O
<b>U.S.</b>	09/020,472 <b>6,234,963</b>	O
<b>PCT</b>	PCT/US99/02798 (National Phase entered)	O (1/2 interest)
<b>U.S.</b>	09/706,512	O (1/2 interest)
<b>Europe</b>	99906848.9	O (1/2 interest)
<b>Canada</b>	2321227	O (1/2 interest)
<b>Australia</b>	26667/99	O (1/2 interest)
<b>Japan</b>	Application No. Unknown	O (1/2 interest)
<b>U.S.</b>	60/263,861	L